|Day Low/High||47.50 / 49.80|
|52 Wk Low/High||29.95 / 58.95|
Patients and their parents willing to pay more for an opioid alternative following wisdom tooth extraction to avoid side effects and risk of addiction
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,240,223 share decrease in total short interest for Pacira Pharmaceuticals Inc. , to 5,113,726, a decrease of 19.52% since 02/28/2017.
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the November 17th expiration.
Collaboration will develop and standardize evidence-based, low-opioid strategies across Trinity Health's 22 states to benefit people and communities
Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.
Pacira (PCRX) reported mixed fourth quarter results.
The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 836,945 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 6,219,273, an increase of 15.55% since 01/13/2017.
Pacira Pharmaceuticals, Clearside Biomedical and Organovo Holdings are among the premarket biotech movers on Wednesday.
EXPAREL® Provides Orthopaedic Patients Long-Lasting, Non-Opioid Postsurgical Pain Control at the Surgical Site
EXPAREL net product sales driven by soft tissue and orthopedic procedures
Typically, the best way to get sentiment to turn is to take the indexes down.
Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2017 expiration.